ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual London Healthcare Conference
ImmunoGen, Inc. (Nasdaq: IMGN) announced that CFO Susan Altschuller and CMO Anna Berkenblit will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 12:00 PM ET. The event will be accessible via a live webcast on the company's website, with a replay available afterward. ImmunoGen focuses on developing advanced antibody-drug conjugates to enhance cancer treatment outcomes, emphasizing their commitment to targeted therapies with improved efficacy and tolerability.
- Participation in a prominent virtual healthcare conference may enhance visibility and investor interest.
- Focus on developing advanced antibody-drug conjugates aligns with growing demand for targeted cancer therapies.
- None.
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Virtual London Healthcare Conference. The presentation is scheduled for November 18, 2020 at 12:00pm ET.
A webcast of the presentation will be accessible through the Investors and Media section of the Company's website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
